PMID- 22311630
OWN - NLM
STAT- MEDLINE
DCOM- 20120716
LR  - 20191210
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 18
IP  - 2
DP  - 2012 Mar-Apr
TI  - Interactions of oversulfated chondroitin sulfate (OSCS) from different sources 
      with unfractionated heparin.
PG  - 166-73
LID - 10.1177/1076029611421167 [doi]
AB  - In 2008, oversulfated chondroitin sulfate (OSCS) was identified as the main 
      contaminant in recalled heparin. Oversulfated chondroitin sulfate can be prepared 
      from bovine (B), porcine (P), shark (Sh), or skate (S) origin and may produce 
      changes in the antithrombotic, bleeding, and hemodynamic profile of heparins. 
      This study examines the interactions of various OSCSs on heparin in animal models 
      of thrombosis and bleeding, as well as on the anticoagulant and antiprotease 
      effects in in vitro assays. Mixtures of 70% unfractionated heparin (UFH) with 30% 
      OSCS from different sources were tested. In the in vitro activated partial 
      thromboplastin time (aPTT) assay, all contaminant mixtures showed a decrease in 
      clotting times. In addition, a significant increase in bleeding time compared to 
      the control (UFH/saline) was observed. In the thrombosis model, no significant 
      differences were observed. The OSCSs significantly increased anti-Xa activity in 
      ex vivo blood samples. These results indicate that various sources of OSCS affect 
      the hemostatic properties of heparin.
FAU - Gray, Angel
AU  - Gray A
AD  - Department of Pharmacology, Loyola University Chicago, IL, USA.
FAU - Litinas, Evangelos
AU  - Litinas E
FAU - Jeske, Walter
AU  - Jeske W
FAU - Fareed, Jawed
AU  - Fareed J
FAU - Hoppensteadt, Debra
AU  - Hoppensteadt D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20120206
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Sulfates)
RN  - 0 (Tissue Extracts)
RN  - 9001-26-7 (Prothrombin)
RN  - 9002-04-4 (Factor IIa)
RN  - 9005-49-6 (Heparin)
RN  - 9007-28-7 (Chondroitin Sulfates)
SB  - IM
MH  - Animals
MH  - Anticoagulants/*pharmacology
MH  - Blood Coagulation Tests
MH  - Cattle
MH  - Chondroitin Sulfates/chemistry/isolation & purification/*pharmacology
MH  - *Drug Contamination
MH  - Drug Interactions
MH  - Drug Recalls
MH  - Factor Xa Inhibitors
MH  - Fibrinolytic Agents/chemistry/isolation & purification/*pharmacology/therapeutic 
      use
MH  - Hemorrhage/chemically induced
MH  - Heparin/isolation & purification/*pharmacology/therapeutic use/toxicity
MH  - Jugular Veins
MH  - Male
MH  - Prothrombin/antagonists & inhibitors
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sharks
MH  - Skates, Fish
MH  - Species Specificity
MH  - Sulfates/analysis
MH  - Swine
MH  - Thrombosis/prevention & control
MH  - Tissue Extracts/chemistry
EDAT- 2012/02/09 06:00
MHDA- 2012/07/17 06:00
CRDT- 2012/02/08 06:00
PHST- 2012/02/08 06:00 [entrez]
PHST- 2012/02/09 06:00 [pubmed]
PHST- 2012/07/17 06:00 [medline]
AID - 1076029611421167 [pii]
AID - 10.1177/1076029611421167 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2012 Mar-Apr;18(2):166-73. doi: 
      10.1177/1076029611421167. Epub 2012 Feb 6.